We need answer legal analysis. Need produce comprehensive. Need reason thoroughly.

We need parse facts and laws. Need answer all assignment bullets. Need be counsel. Need apply supplied rules. Need maybe discuss securities fraud, materiality, scienter, primary liability, control person? Need not cite cases except maybe supplied. Need practical 48h plan. Need include numbers.

Let's understand facts.

Northgate Metrics, private software company, Series B $40M at $220M pre-money. Deck states ARR: $14.2M. Net revenue retention: 138%. Due diligence surfaced composition: includes $2.6M one-time implementation-services fees and $1.1M contract signed but not yet live, terminable by customer on 60 days' notice before go-live. Recurring subscription revenue standard definition approx $10.5M. Retention computed on customer cohort excludes two largest accounts lost during year; including them retention 111%.

CFO email: "Everyone counts pipeline-adjacent. Keep the number. We can true it up after the round." in diligence folder. Deck final slide general disclaimer projections involve risks/uncertainties.

Anchor investor wired $8M first tranche two weeks ago under signed subscription agreement, based on deck. Remaining $32M committed by term sheet but unsigned, signing in twelve days. Founder selling $4M own shares to incoming investors. Yesterday second-largest customer, 9 percent of subscription revenue, delivered non-renewal notice effective term end in four months. No investor knows.

CEO proposes sign on schedule; fix metrics deck Series C. Board meets two days.

Need analyze: Are ARR/retention misstatements present fact or protected projections, applying rules to each number and disclaimer.

Need assess materiality quantify gaps and total mix including non-renewal notice.

Scienter effect CFO email; who exposed company, CFO, CEO, directors.

Anchor wired $8M: options, correction can/cannot cure, rescission should be offered.

Unsigned $32M: correction before signing accomplishes under reliance rule; corrected disclosure must contain, including non-renewal.

Founder secondary $4M in light of nonpublic non-renewal: may proceed, conditions, or pulled.

Board's position under candor/oversight if follows CEO; exculpation and insurance consequences knowingly.

Repricing conversation: present corrected metrics, likely valuation impact, delay/reprice/restructure best protects.

Concrete 48-hour plan.

Need integrate Rule 1: securities antifraud private placements; material misstatement/omission; scienter includes recklessness. Rule 3 projections protected with meaningful cautionary language; not misstatement present/historical. Rule 4 correction before irrevocably committed cuts off reliance. Rule 5 person sells securities while in possession of material nonpublic info about issuer to buyer without info violates antifraud; includes founder secondary. Rule 6 directors duty of candor and good-faith oversight; approving financing known to rest on misleading materials implicates loyalty, not care. Rule 7 indemnification and D&O insurance no cover fraud finally adjudicated.

Need answer nuanced. Let's define ARR: Annual Recurring Revenue. "ARR: $14.2M." Present fact? It is a metric, not projection. Includes $2.6M one-time implementation fees and $1.1M signed not live terminable. Recurring subscription $10.5M. Is the ARR statement misstatement? Yes, overstated by $3.7M? Let's calculate: $14.2M - ($2.6M + $1.1M) = $10.5M. Wait $14.2 - 2.6 - 1.1 = 10.5. But maybe implementation fees could be ARR? no, one-time fees not recurring. Signed not yet live with 60-day termination before go-live: not current revenue/ARR (maybe backlog or contracted but not live; no recurring revenue yet; customer can terminate). So true recurring subscription ARR approx $10.5M. Overstatement $3.7M / 26.1%? 3.7/14.2=26.1%. If "ARR" includes current annualized value of subscriptions? $10.5M. Need maybe note if implementation fees are not recurring and no ARR. Contract signed but not live could be RPO/backlog, but not current ARR and subject to termination. At best contingent, not a present metric. So misstates present fact, not projection. Deck's general disclaimer cannot protect; it is not meaningful, not specific to ARR definitions; "projections" language doesn't convert historical/current metric into forward-looking statement. Even if "pipeline-adjacent" no disclosure.

Retention 138%: Need clarify "Net revenue retention" normally measures recurring revenue retained/expanded from existing customers over period, typically excluding new logos, often includes upsells and contractions; 138% means existing cohort grew 38% net. The figure was computed excluding two largest accounts lost during year; including them retention 111%. This is a material misstatement / misleading. It is present/historical fact (calculation methodology); not projection. Excluding lost accounts distorts cohort; 138% vs 111% difference 27 percentage points? 138 - 111 = 27; growth 38% vs 11%? Need calculate net dollar retention: NDR = (beginning ARR + expansion - contraction - churn) / beginning ARR. Excluding two largest lost customers yields 138%, including them 111%. That's huge. It may be a non-GAAP/operating metric; presentation must not be misleading; selected cohort excluding known lost customers is misleading. Need discuss "total mix": investors use retention as key SaaS quality indicator. Deck says 138% while true 111%. Material. A 27pt overstatement and ARR 26% overstated plus non-renewal = material.

Need discuss "protection does not extend to misstatements of present/historical fact; boilerplate cautions not meaningful." The final slide disclaimer: "projections involve risks/uncertainties" - general. It does not identify "ARR" as projection or define it; not meaningful cautionary language. It doesn't warn of one-time fees included or lost accounts excluded. Therefore no safe harbor for Rule 3.

Materiality: quantify gaps and total mix. Need maybe ARR gap from $14.2 to $10.5 = $3.7M (26%). Retention 138 vs 111 (27 pts). Non-renewal 9% of subscription revenue at term in four months; after correcting ARR to 10.5, this customer is $0.945M subscription revenue annually? 9% of $10.5M = $945k. It ends in four months, likely lost. Need consider if non-renewal notice itself is material nonpublic info; yes: second-largest customer, 9% subscription revenue, non-renewal effective term end in four months. A reasonable investor would consider important; in total mix maybe very significant. But careful: The company may have months until terms end; but notice is a known negative event. It must be disclosed in corrected materials, and for secondary it is MNPI. We need apply "total mix": materiality viewed as substantial likelihood reasonable investor would consider important; not necessarily "would significantly alter total mix"? It says "important, viewed against total mix." So yes.

Need maybe quantify total revenue impact if adjusting ARR and adding non-renewal? Could say corrected run-rate is $10.5M; and disclosed known upcoming loss of $0.945M (9% of subscription revenue) maybe future ARR after 4 months at risk. For valuation, if applying e.g. 15-20x ARR, $3.7M ARR overstatement = $55.5M-$74M? Wait $220M pre at $14.2M ARR => ~15.5x. Corrected $10.5M maybe same multiple? If valuation adjusts, pre-money perhaps ~$163M? Let's compute 220/14.2=15.49x. Times 10.5 = 162.6. Add impact of 9% loss = 9.45M? Hmm 10.5*0.09 = 0.945M ARR at risk, at 15.5x = 14.7M. Also retention differences. But maybe not necessary. Need "repricing conversation" likely address. Need maybe mention if market multiple for quality retention maybe higher/lower. But likely corrected metrics could reduce valuation to $160-170M? Need be careful not overstate. The pre-money was $220M based on 14.2 ARR ($15.5x). Corrected recurring subscription revenue $10.5M; at same multiple, pre-money $163M. But there are other factors, implementation revenue has value but not recurring, maybe lower multiple; signed not live contract maybe pipeline not ARR. Non-renewal would further reduce. So likely $40M round needs repricing/renegotiation; investors may want lower valuation and protect. Need discuss "delay/reprice/restructure" options. Need maybe recommend delay or reprice? Given facts, board meets in 2 days, signing in 12 days. Need correct before signing. But existing anchor $8M already wired under signed subscription agreement based on false deck; must address rescission/remediations. Need decide whether to offer rescission. Could renegotiate anchor? Need options.

Let's think of anchor investor specifics. Anchor signed subscription agreement, wired $8M first tranche two weeks ago. They are "irrevocably committed"? Signed subscription agreement = legally bound; money wired. Rule 4: "A purchaser induced by material misstatement may pursue damages or rescission. Correction of a misstatement before an investor becomes irrevocably committed can cut off reliance for that investor." The anchor already became irrevocably committed when they signed and wired? Yes. Correction now cannot cut off reliance because commitment already occurred; they can claim reliance on original misstatements. But maybe if they don't rescind and agree to continue, with full disclosure and re-pricing? Need "what correction can and cannot cure for that investor": It can cure going forward/waive/rescission? Let's parse.

Rule 4 says correction before investor becomes irrevocably committed can cut off reliance for that investor. Since anchor committed before correction, correction does not cut off reliance; they retain rescission/damages claim unless they knowingly reaffirm/waive after disclosure and maybe new consideration? Correction cannot retroactively cure their original tainted decision. It can provide basis for new agreement/ratification. Need possibly offer rescission or amended subscription agreement. "Correction of a misstatement before an investor becomes irrevocably committed can cut off reliance for that investor." Thus anchor's reliance is arguably established if they can show material misstatement; no post-hoc correction can defeat. Company has liability exposure. Options: notify anchor, offer rescission of the $8M tranche (return subscription price? likely with interest? The facts say wired $8M; if rescind, return funds, unwind shares, maybe rescission also terminates investor status). But company may need funds; maybe negotiate: disclose, get anchor to agree in writing to reaffirm/waive after corrected disclosure, perhaps with amended economics (e.g. conversion price adjusted, additional warrants, most-favored nation) and no rescission; or if not, rescind to limit exposure and litigation. Need maybe "should rescission be offered?" Yes. Given signed subscription agreement based on material misstatements and anchor can rescind; if company doesn't offer, anchor could sue for rescission/damages; litigation risk. Proactively offering rescission, or a reaffirmation with corrected info and compensation, is prudent. Need include "company's options": Keep funds with waiver/reaffirmation; rescind and return; reprice tranche; if rescission offered and investor accepts, liability ended? Need discuss.

Need think about company's liability to anchor if misstatement in deck used "with every prospective investor" and anchor "based on deck." If founder secondary is part of round? Anchor's subscription is for shares? "anchor investor wired $8 million first tranche under signed subscription agreement" likely buying company stock, not founder. They can rescind under Rule 4. Company may have to pay back. No issue of founder secondary to anchor? Founder secondary $4M to incoming investors maybe includes anchor? Need not. Need mention.

Need apply Rule 1 to private placements: It is unlawful to make untrue statement of material fact/omit material fact necessary to make statements not misleading. Scienter includes recklessness. The deck statement used with every investor. The CFO email shows knowledge. Need maybe "company" can be liable? The company is the maker; company acts through officers/directors. CEO/CFO maybe have primary liability if they "make" statements? In private placement, Section 17(a)? Rule 10b-5; primary liability to those who make misstatements. We can apply: CFO made/approved or knowingly kept numbers; CEO proposing sign on schedule with knowledge? Need parse "CEO proposes sign on schedule... fix metrics deck C." Does CEO know? Facts say CEO proposes after problem surfaced; likely knows. Need identify who exposed.

Need "scienter: the effect of CFO's email, and who is exposed, company, CFO, CEO, directors." Need detail:

- CFO email is smoking gun. It shows actual knowledge that metric is inflated/wrong ("Everyone counts pipeline-adjacent" "Keep the number. We can true it up after the round.") That is at least reckless, likely knowing. It defeats good-faith/no-knowledge defenses. It exposes CFO to liability/contribution? As a control person? Under Rule 1 (Securities Act? Rule 10b-5) "scienter includes recklessness"; CFO's email is evidence of scienter and maybe he "made" the misstatement by supervising deck metrics. At least as control person or primary actor if he caused/approved. Need perhaps say "in a private placement, officers can be liable as persons who engage in manipulative/deceptive acts; Section 15 of Securities Act? Actually for private placements under Section 12(a)(2) maybe "seller" liability. But supplied law only says "in connection with purchase/sale security..." It doesn't specify statutes. We need fit. We can say under supplied antifraud rule, anyone who makes/participates in false statement or omission with scienter exposed. CFO likely exposed to SEC/private damages/indemnification not cover fraud. CEO: exposed if he knows of the corrected facts and nevertheless authorizes continued sale/use of deck; at minimum reckless, maybe knowing. He has actual knowledge before signing; cannot hide by "fix later." CEO certifying or controlling? The CEO's proposal is adoption of misstatement. Directors: exposed if they approve financing known to rest on misleading materials; Rule 6 says implicates loyalty, not merely care. If board with knowledge votes to proceed without correcting, that's bad faith/breach duty of loyalty and candor; directors exposed to derivative liability? Under Delaware? But supplied law: duty of candor/shareholders; good-faith oversight. Approving knowingly misleading financing implicates loyalty; exculpation not available for loyalty violations or bad faith. D&O insurance no cover fraud finally adjudicated. Directors who know and approve might be liable for breach of fiduciary duty (and maybe as control persons?); if they don't know but fail to oversee, maybe care not exculpated? Need explain.

- Company exposed: The company is liable for misstatements in its offering documents; may face rescission, damages, indemnification obligations? The company may be liable to anchor/investors, also to founder? Need maybe "company itself cannot assert scienter? It knew through agents; under agency, CFO/CEO knowledge imputed." In securities law, corporate scienter can be established by officers' knowledge. Need mention.

Need perhaps distinguish "directors" under Rule 1: The rule imposes liability on persons who make untrue statements; board may not "make" statements but Rule 6 specifically says duty of candor and good-faith oversight; approving financing known to rest on misleading materials implicates loyalty. Need use provided rules not common law.

Need "directors owe duty of candor to shareholders and good-faith oversight of company's disclosures. Approving a financing known to rest on misleading materials implicates loyalty, not merely care." So if board follows CEO's proposal, they breach duty of candor and oversight. Need say their duty is to shareholders, and here all shareholders because dilution at inflated valuation; perhaps founders and existing investors are harmed if new investors later sue/rescind; board must correct.

Need "exculpation and insurance consequences of proceeding knowingly." Under Rule 7, indemnification and D&O insurance do not cover liability finally adjudicated to arise from fraud. If board knowingly approves/participates in fraudulent financing, no exculpation. If only negligent failure, maybe exculpation, but this is knowing. Need maybe say "knowing misconduct/fraud" not covered, perhaps not indemnifiable; D&O insurer may reserve rights. It may also trigger advancement clawback. Need articulate.

Need "The unsigned $32 million: what correction before signing accomplishes under reliance rule, and what corrected disclosure must contain, including customer non-renewal."

Need think: Remaining $32M committed by term sheet but unsigned; signing in 12 days. Under Rule 4, if company corrects before an investor becomes irrevocably committed, the correction cuts off reliance for investors who sign after correction. What does "correction" have to contain and how delivered? Need correct all investors/prospective investors, not just final slide? Since term sheet signed but subscription agreements unsigned; term sheet maybe non-binding "committed" but not signed. Need maybe be careful: "committed by term sheet but unsigned" contradictory? A term sheet is usually non-binding; committed by term sheet but unsigned subscription agreement? It says "remaining $32 million is committed by term sheet but unsigned, with signing in twelve days." They are not irrevocably committed if documents unsigned; however "term sheet" may bind? Need apply supplied rule: They aren't irrevocably committed because subscription agreement unsigned; correction before signing can cut off reliance. But if term sheet contains conditions? Need say to be safe confirm no other binding commitment or payments. Need update the offering materials and get written acknowledgment that the investor received corrected metrics before signing; maybe include a "blackline" of corrected ARR/retention disclosure and no reliance on prior deck. This creates clear record.

Need corrected disclosure must contain:
- Correct ARR: $10.5M recurring subscription revenue, excluding one-time implementation fees ($2.6M) and signed-not-live terminable contract ($1.1M). Explain definitions, reconciliation from $14.2M if the historical deck remains; perhaps say prior presentation was in error and is withdrawn.
- Correct net revenue retention: 111% on total customer cohort including two largest lost accounts; not 138% excluding them; explain methodology/cohort. If want to present 138% somehow? No; must not use. Maybe can show expansion cohort details if not misleading.
- The $1.1M signed but not live contract should be described as backlog/contracted future revenue, subject to 60-day termination before go-live, not included in ARR. Implementation-services fees should be disclosed as non-recurring and excluded from ARR.
- Non-renewal notice from second-largest customer (9% of subscription revenue) effective in four months; describe customer concentration and expected revenue impact; update risk factors.
- Maybe any other material info needed to avoid misleading; but based facts.
- Include meaningful cautionary language for any forward-looking statements, not boilerplate. But corrected metrics are current facts, not projections. If they include future expectations, must be specific cautionary language.

Need also mention to correct anchor before/ simultaneously. For unsigned: if correction delivered before signing, new investors cannot claim reliance on stale deck, assuming the corrected materials are complete and no other omissions. Under Rule 4, "correction before irrevocably committed can cut off reliance for that investor." It doesn't necessarily cure all liability if the corrected disclosure contains new material? But if it corrects prior misstatement and includes all material facts, they purchase on corrected basis. Need make sure "reliance" is element under Rule 1? It says "A purchaser induced by material misstatement may pursue damages or rescission. Correction ... cut off reliance." So yes.

Need "founder's $4 million secondary in light of nonpublic non-renewal notice: may it proceed, on what conditions, or must it be pulled."

This is insider trading/misappropriation? Rule 5: "A person who sells securities while in possession of material nonpublic information about the issuer, to a buyer without that information, violates the antifraud rules. This includes founder secondary sales in a private financing." So founder cannot sell if she knows non-renewal notice unless either the information is disclosed to buyer before irrevocable commitment, or the buyer already has it, or perhaps the sale terms/conditions? But because this is a registered? Private secondary sale; she is in possession of MNPI. Need determine: non-renewal notice is MNPI. Founder is selling $4M of own shares to incoming investors. She cannot sell unless the specific buyer is informed of non-renewal (and all corrected metrics) before commitment. But there is also the company's corrected disclosure to all investors? If the general investor disclosure includes non-renewal before buyer signs, then buyer has it, so no info asymmetry. But if founder proceeds under CEO "fix later" plan, no. Need maybe say "may proceed only on corrected disclosure and only if there is no other MNPI; ideally after board reviews, and after the buyers sign with knowledge; even then risk remains if buyer not specifically aware." But under Rule 5, if she sells while in possession of MNPI to a buyer without info, violation. If information is disclosed to buyer, not "without that information." So condition: disclose to buyer; give investor time to consider; maybe have founder and company not accept secondary funds until the corrected disclosure has been delivered and acknowledged. But also there may be an issue with secondary as part of round: The entire round is tainted by misstatements. Founder secondary should likely be pulled or at least deferred because of insider trading and because the corrected valuation may be lower; selling $4M at $220M pre while she knows material non-renewal is risky. Need maybe recommend pulling secondary or postponing until after the Series B closes with corrected disclosures and perhaps after the non-renewal becomes public? If Northgate is private, "public" not available; but disclosure to buyer suffices. Since all buyers will receive corrected info before signing, founder can sell on same corrected terms, but "nonrenewal notice effective at term end in four months" is material. With correction, buyer is not without info. Need answer "may it proceed, on what conditions, or must it be pulled." Need discuss both legal and practical.

Potential additional issue: If the company corrects ARR/retention and non-renewal before signing, valuation will drop. Founder selling at a corrected lower price? If existing term sheet remains at $220M with non-renewal undisclosed, it's not fair; investors may demand reprice. If the round reprices downward, founder's secondary price may adjust accordingly. She may prefer pull; but if she proceeds, the company should receive fairness opinion? Not necessary.

Need maybe say "must be pulled" in the current form." Because at the scheduled signing, if the CEO's proposal is followed, no correction; then founder sells while in possession of MNPI. That is per se violation under Rule 5. Under a corrected signing, it may proceed, but perhaps only if board concludes price fair after correction and all buyers sign after receiving full disclosure. However, because founder is a seller and will possess non-renewal, the safest legal course is to suspend the secondary until either the non-renewal has been disclosed and the transaction can be renegotiated, or no sale. Given a "should rescission be offered" context, likely recommend pulling founder's secondary or at minimum postpone. Need phrase: "Not on the current terms or current disclosure. It may proceed only after full corrected disclosure and re-pricing/acknowledgment (and even then, if the information remains non-public but disclosed to buyers, Rule 5 is satisfied); unless investors are unwilling to buy after disclosure, in which case it is pulled."

Need "The board's position under candor/oversight rules if it follows CEO's proposal, and exculpation/insurance consequences of proceeding knowingly."

Need include:
- Board should not follow; following CEO = knowingly authorizing sale of securities using false ARR/metrics and non-disclosed nonrenewal. This violates Rule 1 (company/individuals) and Rule 5 for founder secondary.
- Breach duty of candor: failing to disclose material facts to shareholders; breach oversight: failing to ensure disclosures accurate.
- Because "approving a financing known to rest on misleading materials implicates loyalty, not merely care." Delaware section 102(b)(7) would not exculpate loyalty/bad faith; Rule 7 excludes indemnification/insurance for fraud. D&O policies may have fraud exclusions; no coverage for knowingly fraudulent conduct; perhaps advancement can be denied if adjudicated. Board minutes should reflect refusal.

Need maybe mention "good-faith oversight" means if board lacks knowledge, they'd need inquiry after being notified; if they willfully blind/ignore CFO email, that's recklessness. Since board meets in two days with notice, if they don't correct, they act knowingly/recklessly.

Need "repricing conversation: how to present corrected metrics, likely valuation impact, and whether delay, reprice, or restructure best protects company."

Need think strategic advice.

How to present corrected metrics to investors:
- Go to investors before scheduled signing; do not wait. Script? Need maybe "we discovered an error in our metric presentation; corrected ARR is $10.5M; corrected net revenue retention is 111%; here's reconciliation; nonrenewal; we are implementing controls; offer rescission to anchor; renegotiate terms."
- Emphasize underlying business, cash? But no hype; no self-serving caution. Provide board-approved corrections, CFO/CEO accountability? Perhaps "we are replacing CFO?" Not needed.
- "The business is real" may be true; use actual retention 111% (still healthy if retention above 100) and implementation revenue $2.6M as real non-recurring revenue; signed $1.1M contract as backlog under conditions. But don't call ARR. Correcting lowers headline metrics but may preserve trust; if company delays, trust destroyed.
- Valuation impact: Based solely on ARR multiple, $220M pre at $14.2M = ~15.5x; at $10.5M same multiple => ~$163M pre. But because "ARR" quality and retention overstated, market multiple may actually be lower; $2.6M implementation services not recurring and $1.1M not live; non-renewal of 9% subscription revenue means current run-rate not recurring after term; need maybe adjust further. If corrected ARR at $10.5M and known loss of $0.945M, forward annualized recurring revenue run-rate after four months = $9.555M, but wait if contract ends in four months, it still contributes for four months; annualized after churn approx 10.5 - 0.945 = 9.555. The current run-rate could be $9.555M going forward? Actually if $0.945M annual subscription revenue stops after four months, then if annualizing current month at end of term, yes. But at signing now, customer still has 4 months, but investors should know. A 15.5x multiple on $9.555M = $148M pre. But maybe implementation revenue also contributes revenue and cash but not ARR; not zero value. $2.6M implementation fees maybe one-time but part of current year revenue and cash; valuation could include at lower multiple. The $1.1M signed contract maybe not live but probability high; perhaps some value but not ARR. Need not precise.
- The actual pre-money should be negotiated not by formula; corrected ARR is lower by 26%, retention from 138 to 111, non-renewal. I'd expect investors to seek a valuation at or below ~$150M-$165M pre; round size might be reduced to avoid dilution? Need maybe not give exact valuation but provide sensitivity. Need be careful; as counsel, avoid valuation advice? But assignment asks likely valuation impact. We can provide framework. "If the pre-money was set at 15.5x published ARR, applying that to corrected ARR yields $163M; after making explicit allowance for nonrenewal and quality discount, round may be priced closer to $140-160M, depending on negotiation; no guarantee." Need "whether delay, reprice, or restructure best protects the company."

Options:

1. Delay signing: advisable? We don't have enough time to fix metrics? 48-hour plan can correct. Delay might avoid signing without corrected disclosure. But delaying too long may cause loss of investor confidence, need cash. If current investors are willing, better to reprice than delay? Need maybe recommend "delay only if needed to obtain signed corrected documents; don't sign on schedule without correction." The assignment "whether delay, reprice, or restructure best protects the company." Need choose.

- Delay: If the company needs time to prepare corrected audited/sourced metrics, confirm nonrenewal details, anchor remediation, board. Delay is the minimum. But can it still sign in 12 days? Maybe yes, with 48-hour plan, but more time may be needed. However "delay" alone does not solve mispricing; investors may use delay to investigate and demand lower price. It protects from fraud liability but creates uncertainty.
- Reprice: This is likely necessary: correct the pre-money valuation and per-share price to reflect corrected metrics. Existing anchor gets amended subscription agreement; remaining investors get amended terms; founder secondary price adjusted. Reprice best balances: preserve round and trust, while eliminating reliance/investor claims. But reprice alone? Need also correct disclosures/process.
- Restructure: Options include: reduce round size, convert some equity to convertible notes? Raise bridge at lower valuation, delay Series B until metrics improve, replace primary equity with notes; pull founder secondary; offer anchor rescission/replacement; adjust tranches/timing; add investor protections. If investors won't invest at corrected valuation, company may need bridge. But because $8M anchor already wired, maybe company can keep it under amended terms or return. Restructure may be best if valuation gap cannot be bridged or if investors lose confidence. Could include "repricing plus bridge, lower round size, warrants, most-favored-nation, and no founder secondary until closing." Need maybe recommend: "Immediate correction; offer anchor remediation; reprice; if investors won't agree, delay and bridge/restructure. Do not sign on schedule."

Need "repricing conversation" details:
- Present corrected metrics first; don't pair with ask? "Let us show you what the business actually is and what it is worth."
- Have prepared reconciliation table: Old metric, corrected metric, definition, source.
- Quantify: ARR $14.2 -> $10.5; NDR 138% -> 111%; non-renewal 9% subscription revenue ($0.945M).
- Explain root cause and controls (CFO email? Maybe don't disclose email? But if asked, be honest; likely cannot hide. Need decide: privileged? Facts say email in diligence folder. It may be discoverable. Board should not suppress. Corrective disclosure should state metric error; maybe not quote internal email unless necessary. Need not include "everyone counts pipeline-adjacent" in external disclosure? Could say "management was aware and failed to correct" if asked. Need perhaps not throw CFO under bus? But to avoid future litigation, disclosures need be candid. However a public or investor disclosure of internal email may create admissions. But as counsel, I'd advise not to characterize as intentional unless necessary? Hmm. Need be careful: The assignment asks legal analysis, not litigation strategy. We need address.

Need perhaps discuss "corrective disclosure" content includes "previous metrics were incorrect and should not be relied on; we will restate." Maybe not "fraud." But if CFO email exists, "we can't certify no knowledge." Anchor's rescission claim likely. Need maybe say "Don't sign a 'fix later' plan; later cannot cut off reliance; it just adds fraud."

Need maybe mention "Rule 3" and "safe harbor" with "forward-looking statements accompanied by meaningful, specific cautionary language" maybe no issue because metrics are current facts. The deck disclaimer is "projections involve risks and uncertainties" but the deck doesn't label ARR/retention as projections. It is boilerplate. For any forward-looking statements, e.g. if they say "we expect retention to continue" need specific cautionary language around risks, not generic.

Need maybe mention "statements are misleading even if literally true?" The ARR number maybe not an untrue statement if there is a different definition? But if it includes non-recurring fees and non-live contracts, calling it ARR is inherently false because ARR by definition recurring revenue; or at least materially misleading because accepted definition. Need maybe say "At minimum, half-truth: not false in abstract but omission of composition makes it misleading." Under Rule 1, omission of material fact necessary to make statements not misleading. Need discuss.

Potential nuance: The $2.6M implementation-services fees may be one-time, but could be billed annually? "one-time implementation-services fees" = non-recurring; cannot be in ARR. The $1.1M signed not yet live, terminable on 60 days before go-live: maybe "contracted ARR" if signed, but not live; standard definition? If the customer pays? "not yet live" means service not started; customer can terminate; not a current recurring revenue stream. At most backlog, not ARR. Need maybe include "even if you used a non-standard definition, you'd have to disclose definition and material non-recurring items; not done." Need maybe mention "pipeline-adjacent" in CFO email confirms he intentionally included pipeline/backlog.

Need maybe discuss "Net revenue retention" and "cohort" nuance: NRR is always measured on a cohort; excluding churned customers is not necessarily always wrong if measuring only "logo retention" of existing customers? Wait, NRR is measured on a defined cohort of customers that existed at start of period; if you exclude customers that churned during period, you're measuring only remaining customers, not "net revenue retention" of the starting cohort; this artificially inflates. It could be "net revenue retention of retained accounts" but not labeled. Thus misleading. Need include.

Need maybe discuss "non-renewal notice" in corrected disclosure: Since customer non-renewal is negative but maybe confidential. It is MNPI for founder secondary. It should be in corrected materials because it concerns future revenue and known uncertainty. Need quantify: customer is 9% of subscription revenue = approx $0.945M annualized. But if it's second-largest, 9% of subscription revenue; maybe 9% of $10.5M = $945k; if 9% of ARR true. Need maybe say "assuming the 9% is of corrected subscription revenue, approximate $0.9M; if based on previously reported number, material anyway." Need decide. Facts "second-largest customer, 9 percent of subscription revenue" likely of corrected subscription revenue (or current). Use approx.

Need "materiality: quantify gaps and assess them against total-mix standard, including non-renewal notice."

Need perhaps structure:
- ARR overstated by $3.7M (26%) from true recurring $10.5M. A 26% ARR overstatement for an early-stage software company is material: ARR is headline metric; valuation often multiple of ARR; investors rely. $14.2M vs $10.5M is difference between crossing $10M ARR milestone and not? Actually both >10 but yes. At 15.5x, $57.35M valuation gap? Let's calculate: 3.7*15.5 = 57.35. That's huge. Maybe use to show materiality.
- Retention overstated by 27 percentage points; 138% vs 111% is difference between best-in-class and average? Actually 111% NRR is still positive but 138% is exceptional. Investors consider NRR a key growth/efficiency metric. Material.
- The non-renewal notice: 9% revenue loss in four months; alone material. It must be included; in total mix, combined with inflated metrics, creates materially misleading picture. Even if ARR and retention corrected, failure to disclose nonrenewal could still violate Rule 1/5.
- The materiality of corrections: Because reasonable investor would view old deck as important to investment decision. The total mix includes maybe other strengths (real revenue, business), but no other information dilutes the importance of an 26% overstatement and customer loss; total mix standard doesn't require outcome-determinative.

Need "scienter": maybe include "The CFO email has actual awareness. It may make company's and CFO's conduct knowing, not merely reckless, because CFO was asked months ago, said 'keep the number'; 'true it up after round' shows intent to postpone correction until financing complete; use of 'Everyone counts pipeline-adjacent' shows he knew the number did not reflect standard ARR. It is direct evidence of intent to deceive or at least severe recklessness." Need maybe discuss "CEO: 'fix metrics deck for Series C' shows he wants to use false deck for Series B; actual knowledge; likely primary violator if he authorizes/uses deck; at minimum control person. Directors: if board knows and votes yes, they act with scienter (knowledge/recklessness); if they merely fail to investigate after notice, also reckless. Company: vicarious/agency; corporate state of mind is CFO/CEO knowledge."

Need maybe discuss "who is exposed" in terms of "liability finally adjudicated to arise from fraud" under Rule 7:
- Company: may be liable for rescission/damages; cannot escape because private placement; not exculpated.
- CFO: likely primary violator, no indemnification for fraud; D&O no cover. Employment/termination for cause maybe.
- CEO: if approves knowingly, primary/control; no exculpation.
- Directors: if they knowingly approve, loyalty breach; no exculpation, insurance exclusions; if they act diligently to correct, they can protect themselves.
- Founder: secondary seller; if she proceeds on current facts, insider trading; no indemnification for fraud; also as director? Is founder maybe CEO? Facts "founder is selling" not explicitly CEO? CEO proposes; probably founder/CEO? It says CEO proposes, and founder selling? Could be founder and CEO same? Need not assume? It says "the founder is selling $4 million of her own shares"; CEO proposes; likely founder=CEO? It says called by CEO; "founder is selling"; probably female CEO? We can refer to "founder/CEO" if same? Need be careful. The facts "as part of the round, the founder is selling $4 million of her own shares" and "CEO proposes" maybe same person? It doesn't say "CEO/founder." We can say "the founder (if she is the CEO, then CEO also)..." But probably yes? We need decide. It says "called by its CEO"; "founder is selling her own shares"; "CEO proposes" maybe founder is CEO. But not explicit. We can refer to "founder" and "CEO" separately? In many assignments, founder may be CEO. Need perhaps mention "The founder, if the CEO, is especially exposed; in any event the founder's secondary is separate." We can call "founder/CEO" if consistent? Let's see: "The CEO proposes: 'Sign on schedule...'" "the founder is selling $4 million of her own shares." It does not say "founder-CEO." But in startup, yes. To avoid confusion, use "CEO/founder" after saying "the founder who is also (as appears) the CEO." But the prompt says "Advise company and board"; "founder" and "CEO" maybe same? It says "a private software company, called by its CEO"; "the founder is selling..." likely founder=CEO, "her own shares." It uses female founder; CEO maybe? We'll phrase "the founder/CEO (if the CEO is the founder; if not, both are exposed)." Need not dwell.

Need "indemnification and directors-and-officers insurance do not cover liability finally adjudicated to arise from fraud." Need maybe say "Even if DGCL 102(b)(7) exculpation exists, it does not cover breaches of duty of loyalty, bad faith, intentional misconduct, or knowing violations of law. Under Rule 7, no indemnification/insurance for fraud final adjudication. Thus the board's only protection is to not proceed knowingly."

Need "48-hour plan for counsel: corrective disclosure, anchor remediation, secondary decision, board resolutions, in order."

Need create ordered timeline. Need be practical, maybe "Day 1" and "Day 2" with hours. Need include:
- Immediately: preserve documents (litigation hold), including CFO email; don't destroy; stop further use of current deck; instruct no investor communications without counsel.
- Board meeting/executive session: present legal analysis; no approval of sign-on-schedule; authorize correction, remediation, reprice/delay.
- Prepare corrected disclosure/reconciliation and board resolutions.
- Contact anchor investor first: disclose, offer rescission or amended reaffirmation/reprice; get signed written agreement before any use of $8M. Need maybe sequence: Anchor is already committed; they should be notified before new investors? Yes. Need maybe "offer rescission or amended and restated subscription agreement; if rescission, return $8M promptly; if not, obtain waiver/reaffirmation after corrected disclosure and revised terms."
- Contact remaining investors (those with term sheet but unsigned): deliver corrected deck and amended term sheet; get acknowledgment before signing; if they want to back out, allow.
- Founder secondary: notify founder; decide to suspend/pull until corrected disclosure and buy-side acknowledgment; maybe not proceed until after reprice; possibly pull entirely.
- Board resolutions: record that board did not approve using stale/false metrics; approved corrected materials; authorized CFO/CEO to execute corrected disclosures; approved repricing/delay; appointed special committee? Maybe use special committee of independent directors to negotiate with founder/anchor? Because conflicts: founder secondary and management liability. Need maybe "consider forming special committee of independent directors to oversee corrective disclosure, negotiations involving founder/CFO and to preserve privilege." Good idea. Need include in board resolutions.

Need "in order" maybe:
1. Immediately (hours): litigation hold, pull deck, board special committee, retain advisors.
2. Day 1: draft corrected metrics and reconciliation and nonrenewal; board resolution to correct and not sign on current terms.
3. Day 1: Anchor remediation (rescission/reaffirmation) before any other new money; founder secondary pulled/suspended.
4. Day 2: deliver corrected disclosure to remaining investors; renegotiate terms; update term sheets; get acknowledgments; if cannot agree, delay/restructure.
5. Follow-up: board meeting minutes, controls, maybe CFO termination? Need maybe not in 48h.

Need maybe "board resolutions" in 48-hour plan include:
- Resolved that the prior ARR/retention figures in the Series B deck are withdrawn and restated; corrected disclosure attached.
- Resolved not to proceed with any issuance or founder secondary using prior deck.
- Resolved to authorize officers to offer anchor rescission/reaffirmation and negotiate amended subscription agreement, subject to special committee.
- Resolved to delay signing until corrected disclosure delivered and investors have had reasonable time to consider; no fixed date if necessary.
- Resolved to pull or suspend founder secondary until conditions satisfied; if proceeds, only after full disclosure and board approval.
- Resolved to retain counsel and maybe financial advisor; litigation hold; cooperate.

Need maybe answer "should rescission be offered" explicitly. Yes, probably. But if company is desperate for cash, offering rescission to anchor may drain cash; but not offering is worse. Could maybe "offer rescission or, alternatively, a documented amendment to the anchor's subscription agreement that gives the anchor a rescission right or repricing if not satisfied." But "rescission should be offered" because the anchor has unwaivable? Under Rule 4, they were induced before correction; the company can't cure. If company doesn't offer, anchor can sue; proactively offering rescission may preserve relationship and cap liability. Need phrase: "At minimum, the company must notify anchor and offer them a choice: (i) rescission and return of $8M, or (ii) reaffirm after full corrected disclosure and receive amended economics (e.g., reprice, additional rights). The company should not assume anchor will keep funds; it should honor rescission if requested. A unilateral statement 'we corrected the deck now' does not cure anchor's claim." Need maybe "If the company reprices and anchor signs amended subscription agreement before the remaining $32M closes, this can provide the cleanest basis to keep funds."

Need maybe "Correction before signing accomplishes under reliance rule" with reliance. Need emphasize: "For the unsigned $32M, the correction must occur before they become irrevocably committed, i.e., before execution of subscription agreement and wiring; ideally before they even reconfirm. If so, the old misstatement is no longer the basis of their purchase. But correction must be meaningful: specifically retract old metrics, state correct numbers, disclose nonrenewal, and give investors time to digest. A final-slide boilerplate addition won't do." Need maybe "the term sheet's commitment may be binding in a nonlegal sense? Since no subscription agreement signed, correction before signing is enough under Rule 4; however, if any investor signed an irrevocable commitment earlier, they are like anchor and need remediation." Good.

Need maybe "Correction and rescission interplay": For anchor, if they choose rescission, company returns $8M and cancels shares. If anchor keeps and reaffirms, maybe their original reliance is waived; but because they are a sophisticated investor, waiver after disclosure is enforceable if no fraud? Need maybe note "Securities law generally permits a purchaser to waive rescission after full disclosure; but an ex ante waiver of fraud liability is unenforceable. So don't ask for blanket waiver of future fraud; ask for acknowledgment that they received corrected info and elected to continue." Maybe mention.

Need maybe "non-renewal notice" disclosure and Rule 5: It is MNPI; founder in possession. But also company's corrected materials include it. If disclosed to all buyers, no asymmetry. But "the founder" might have additional MNPI (e.g., future product problems), not relevant. Need maybe "she must also not trade while in possession of CFO's knowledge? If she as director knows all; Rule 5 says any material nonpublic info; after corrected disclosure, still if there is other non-public info not disclosed, can't sell. Need implement "no-trade until after blackout?" Not for private. "If the secondary is part of the round, all investors receive same information; she can proceed once terms reset and no other MNPI." But practical risk.

Need maybe "conditions for secondary" list:
- Full correction first delivered to all buyers; specifically including non-renewal.
- Repricing/adjustment of founder sale price to corrected valuation; no sale at stale inflated price.
- Founder provides written representation that she has no undisclosed MNPI and is not relying on company? Actually seller doesn't rely; buyer relies. Maybe "investors acknowledge receipt of corrected disclosure and that the purchase price reflects it."
- The purchase agreement includes "no other material information" representations? Need maybe not.
- Possibly "independent special committee approves the secondary because of conflict." If founder is director/CEO, need disinterested director approval; if not, still.
- Maybe "secondary should be pulled if there is any doubt."

Need maybe "board's position under candor and oversight rules if follows CEO's proposal" with "known to rest on misleading materials" not "should have known." It implicates loyalty; due to CFO email and CEO proposal, the board would know? The board is told in two days; if it follows, yes.

Need maybe "insurance/exculpation consequences" more:
- Exculpation provisions (e.g., Delaware 102(b)(7)) generally protect for breach of duty of care, not bad faith, intentional misconduct, knowing violation of law, or transactions where director received improper benefit.
- Because approving false offering knowingly is disloyal/bad faith, no exculpation.
- D&O insurance policies exclude fraudulent, criminal, knowing violations; even if advance defense costs, insurers likely reserve rights and seek reimbursement if fraud adjudicated; Rule 7 says no cover. Thus board's assets/personal exposure if knowingly proceeds.
- For directors who act diligently and require correction, they can maintain exculpation and coverage; they should insist on minutes and not delegate blindly.

Need maybe mention "the company's articles/certificate may have exculpation but not for officers? In Delaware, Section 102(b)(7) applies to directors, not officers? There is no exculpation for officers? But in private company maybe charter. Need maybe phrase "charter exculpation, to the extent available, does not protect the CEO/founder as officer; and does not protect directors for loyalty violations." Need maybe not go beyond supplied law. The prompt specifically "exculpation and insurance consequences" maybe under Rule 7. We'll say "even if certificate has 102(b)(7)-type provision, it does not cover this." Need maybe "the company's indemnification obligations may be prohibited because fraud/adjudicated; company may have right to refuse advancement/indemnification."

Need maybe discuss Rule 3 safe harbor "Projections and forward-looking statements accompanied by meaningful, specific cautionary language protected." The corrected metrics could include projections? If the company wants to present "expected ARR after implementation fees" maybe that's forward-looking; needs meaningful caution. Need perhaps mention "corrected metric deck should not include any projections unless necessary; and if it does, include specific risk factors: retention could decline, non-renewal, contract termination." But "Rule 3 protection does not extend to misstatements of present or historical fact" means all corrected metrics should be current facts, not projections. Need maybe "the original deck's statement 'ARR $14.2M' is not a projection even though it says final slide projections; because it is a present assertion. General disclaimer cannot transform it." Good.

Need perhaps "materiality and total mix" includes "the non-renewal notice" as an omitted fact. Need maybe "the non-renewal notice also makes prior retention figure more egregious: they exclude two largest lost accounts; one of those two might be same? Wait second-largest customer delivered non-renewal yesterday; two largest accounts lost during year; second-largest current customer nonrenewal. So there are additional lost future revenue. Need maybe say "in addition to two largest accounts already lost during the year (which were excluded from retention), a third large account has now given notice." Nice.

Need maybe compute "including two largest accounts lost during year, retention is 111%. The second-largest customer non-renewal is at term end in four months; if included in a forward retention calculation, it would lower future retention; but at least disclose." Need maybe not compute.

Potential nuance: "Net revenue retention: 138%" computed on a customer cohort that excludes the two largest accounts lost during the year; including them retention is 111%. Is 111% itself maybe "retention" of starting cohort including churn; yes. But if excluding lost accounts is a non-GAAP metric, if clearly described, maybe could be used to show "retention of remaining customer base" as supplemental. But it wasn't described; and even if described, for "net revenue retention" standard, it's misleading. Need maybe mention "company may include a supplemental retention of continuing customers if material and not confusing; but not as headline."

Need maybe "CFO's email now in diligence folder": "diligence folder" means investors may see it? It is in diligence data room. Anchor/other investors might already have access? Facts "email now in the diligence folder" maybe perhaps due diligence preparation surfaced it; it might be in data room and prospective investors may find. If they already saw it, maybe investors know? But "No investor knows" about nonrenewal; not sure about CFO email. Need maybe "the email is in diligence folder; you must assume it is or will be seen; it is discoverable; not suppress." Good.

Need maybe "correction of misstatement before irrevocably committed can cut off reliance" but "reliance rule" maybe if corrected before any investor signed, no claim; but if investor had seen old deck and then later signed after corrected disclosure, does reliance cut off? The Rule says "Correction before an investor becomes irrevocably committed can cut off reliance for that investor." So yes. Need maybe "The remaining $32M investors are not irrevocably committed until subscription agreement signed and possibly funds wired; correction before signing is effective, but they should get a reasonable period to consider, not just same meeting." To be safe, deliver several days before signing; but signing in 12 days enough. Need maybe "If they signed term sheet, is that irrevocable commitment? Need examine term sheet; a term sheet by itself usually non-binding; if it contains binding provisions (confidentiality, exclusivity, break-up) not purchase commitment. If any commitment was binding before correction, they are anchor-like." Good.

Need maybe "company's options for anchor" legal possibilities:
1. Keep anchor at original terms with full disclosure and written reaffirmation. Does that eliminate anchor's right? If they sign an amendment after disclosure, perhaps yes. But they might demand rescission/repricing; if the company's price drops, they may not want original.
2. Rescind anchor by agreement: return $8M (plus interest? maybe no statutory interest under rule, but contractual; need "any amounts due"). Cancel shares; treat as never occurred; then possibly have them reinvest in corrected round if they want, at corrected terms. This is clean.
3. Treat anchor as part of corrected round and amend subscription agreement to new price; if lower price, they get more shares or price protection; if rescission, no more.
Need "should be offered": If the misstatement is material and anchor was induced, the anchor has unilateral rescission; company should "offer" to facilitate resolution. But the company should not frame as admitting fraud? It should use "because we have determined the prior materials contained errors, we are offering you the opportunity to rescind or reaffirm." This may trigger litigation but necessary.

Need maybe "the founder's secondary" and "rescission" maybe if anchor is "incoming investors" includes founder sale? Need "as part of the round, founder selling $4M own shares" - there are incoming investors for primary and secondary. The investors could have a claim against founder individually; if they rescind their purchase from company, can they also claim against founder? If founder sold in same transaction, she is a seller; Rule 5. Need maybe "The founder's shares cannot be issued/resold until corrected disclosure; if the transaction closes and nonrenewal not disclosed, she is personally liable to rescission/damages." Good.

Need "delay, reprice, or restructure best protects company." Let's think of recommended path:
- Reprice is not optional if investors want to continue; but "delay" can be a tactical step if corrected metrics need verification.
- Best approach: "Correct now, reprice the Series B, and restructure the founder secondary (pull it or postpone). If the existing investors won't accept the corrected price, then delay and raise a bridge. Signing on schedule at stale terms is forbidden; rescission risk and board liability. The company should not cling to $40M at $220M; the company's best protection is credibility."
- Maybe "delay" alone doesn't protect; if you delay the signing to correct but at old price, still tainted? Wait if you correct and then sign after correction at same pre-money? If investors know corrected lower ARR but still agree to $220M, that's okay; no fraud. But with rational investors, they won't. If they do, perhaps the company could keep price if investors view future prospects, but the price must be based on corrected info. But at same pre-money, investors may be overpaying if not rational; but if they knowingly agreed, no reliance. Need not force reprice? But board's duty to company maybe obtain fair value? Could be conflict: selling at inflated price to new investors after disclosure? It may not be fraudulent, but could be unfair to investors? In private placement, with sophisticated investors and full disclosure, they can agree. But "board duty" to shareholders might favor higher price; yet misleading prior price not legitimate. Reprice is prudent. Need maybe phrase "At a minimum, the price/valuation must be re-examined in light of corrected metrics; it may not be $220M. Do not assume that simply appending corrected numbers preserves the old valuation."

Need perhaps "corrected disclosure must contain" includes "prior ARR $14.2M was erroneous; correct ARR is $10.5M; prior NRR 138% was erroneous; correct NRR 111%; the two largest accounts lost in period were excluded; the $1.1M signed not-live contract is not ARR and is terminable; the $2.6M implementation fees are non-recurring; customer nonrenewal; risk factors; corrected financial statements maybe." Also maybe "the CFO email"? Should corrected disclosure include the fact that management knew? Hmm. Need decide. Could be omitted? If we fail to disclose that a senior officer had knowledge and company previously intentionally misled, is that itself misleading? For investors deciding whether to trust management, yes, internal misconduct is material. But if board "corrects" by saying "certain prior metrics were incorrect" without saying "CFO knew and instructed to keep the number," is that a half-truth? The assignment perhaps expects discuss. They may need disclose "we discovered errors in metric definitions"; but if the CFO email reveals knowing misstatement, failing to disclose may be an omission material to investor assessment of management integrity/controls. What is required? At least in securities disclosure, disclosure of internal control deficiencies and corrections can be required. But disclosing the email may expose liability. Need balance. The prompt: "The CFO, asked about the definition months ago, wrote in an email now in the diligence folder..." This email may be found by investors; the board may need to address it. The corrected disclosure should likely state "the figures were not a good-faith error; management knew before the anchor investment and did not correct" because otherwise the company would be making a misleading statement about the reliability of corrected disclosures? Need maybe mention "the corrected disclosure should not falsely characterize the error as inadvertent if the CFO email contradicts that." This is important. If the company sends "we regret the error" but omits CFO email, investors later discover, it's another material omission/misstatement. It may also affect rescission/waiver; anchor's waiver after disclosure would be invalid if disclosure incomplete. Therefore the corrective disclosure should candidly state that during diligence, company determined the metrics were improperly calculated and that a senior officer had been aware and directed maintaining the number until after the round; the company is taking corrective action (e.g., CFO reassigned/terminated, process changes). Need maybe caution: "Don't admit fraud unless necessary"? But if an email says "Keep the number. We can true it up after the round," the board must not conceal. In litigation, it will be discoverable. For purposes of counsel, "corrective disclosure must be complete; incomplete correction is no correction."

Need perhaps "The deck's final slide contains general disclaimer that projections 'involve risks and uncertainties.'" Is this "meaningful, specific cautionary language"? No. It doesn't mention "ARR" or "retention" or "projections." It is boilerplate. It might protect some forward-looking statements, not historical metrics. Need maybe "the disclaimer cannot be used as an additional misleading statement? If deck says projections involve risks but does not label ARR projections; no." Need maybe "if the company had labelled the ARR as 'projected ARR' and provided specific cautionary language about inclusion of implementation fees and signed not-live contracts and risk of nonrenewal, it might be protected; but it did not. 'Everyone counts pipeline-adjacent' confirms it was presented as current ARR."

Need perhaps "Rule 1 applies to private placements" so no registration statement liability? Need maybe not.

Need perhaps "reliance and rescission" under Rule 4:
- For anchor wired $8M: They are "irrevocably committed" on signing and wiring. Correction after can't cut off reliance; only before commitment can. Therefore anchor can say "I relied on ARR 14.2/retention 138; if I knew true figures, I wouldn't have invested." They have damages/rescission. Company's options: "correct, reprice, recision/reaffirmation" not unilateral "fix future deck."
- For remaining $32M: Since unsigned, correction before signing can cut off reliance. But "term sheet committed" maybe if "irrevocably committed by term sheet" perhaps need check; term sheet might not include final subscription but if it is a binding commitment "committed" maybe could be considered irrevocable? The wording "committed by term sheet but unsigned" ambiguous. The prompt says "remaining $32M is committed by term sheet but unsigned, with signing in twelve days." It asks "what correction before signing accomplishes under supplied reliance rule" - likely expects correction before signing suffices. Need maybe mention "if the term sheet itself is a binding commitment, those investors are in anchor's position; but if by 'committed' they mean a signed non-binding term sheet, not irrevocable." We need not overcomplicate but mention diligence.

Need perhaps "scienter and 'who is exposed'" maybe includes "outside directors" maybe no operational involvement but after board meeting, they know. If they follow CEO, they have at least recklessness; if they refuse, protected. Need maybe "CFO can be liable even though company is issuer; CEO can be liable because he controlled/authorized; directors can be liable because they knowingly approved; board members have duty of candor." Need maybe "The company may have to honor indemnification if no final fraud adjudication; but not if adjudicated fraud. It may not be able to advance defense costs? Under Rule 7, insurance not cover fraud finally adjudicated; but some policies advance defense costs subject to clawback. Need maybe "do not assume coverage."

Need maybe "founder secondary: may it proceed if nonrenewal notice is material nonpublic information and buyers get corrected materials? "The Rule says 'to a buyer without that information' - if the investors are told before irrevocable commitment, they are not without that information. But if the founder's sale closes as part of a signed agreement that was already signed before correction? The anchor signed before; if founder's secondary part of anchor's purchase? Maybe founder's secondary to "incoming investors" under the round including anchor? If anchor already signed, maybe no founder secondary to anchor? Need parse: "As part of the round, the founder is selling $4 million of her own shares to the incoming investors." The "incoming investors" may be the same group as $40M. Anchor already wired $8M; the remaining $32M committed but unsigned; founder's $4M secondary perhaps part of the same transaction. If anchor's signed subscription included secondary shares? The facts say anchor investor wired $8 million first tranche under signed subscription agreement, based on deck. It doesn't say whether this included founder shares. "The remaining $32 million is committed by term sheet but unsigned... As part of the round, founder selling $4M..." Maybe total round is $40M primary plus $4M secondary? Or $40M includes $4M secondary? It says "scheduled signing of a $40 million Series B financing... As part of the round, founder is selling $4 million own shares to incoming investors." Thus total investor cash maybe $44M? Or $40M includes secondary. Need not decide. For secondary, all investors need corrected info before committing.

Need maybe "the non-renewal notice is known only to company; if the company corrects before signing and includes in data room, then founder can sell if the buyer signs after. But because founder is a control person, any sale by her while company also is selling is automatically suspicious; maybe Section 16/b? no, private."

Need maybe "Rule 5 says person who sells securities while in possession of material nonpublic information about issuer, to buyer without info, violates antifraud." Need maybe "This is similar to Rule 10b-5; no need for misstatement, just possession and trade. The non-renewal notice is MNPI. The founder must not sell unless all buyers know it. She should also refrain from selling if the corrected deck has not been delivered to each buyer; disclosure to one not enough." Good.

Need maybe "board resolutions" include "no director should vote to approve; any director who disagrees should ensure dissent is recorded" to protect. Need include in plan perhaps.

Need maybe "materiality of non-renewal notice" in "corrected disclosure": Since no investor knows, if the company signs on schedule without disclosing, this is an omission "necessary to make statements made not misleading." Does it make ARR/retention misleading? Even if ARR/retention corrected, nonrenewal makes current ARR not representative of future. It is also MNPI for secondary. Need perhaps "non-renewal notice occurred after original deck; it is a subsequent event. Does a duty to update exist? Once using deck and soliciting continuing investments, yes. If original statement was true at time but became false due to subsequent event, company must update/supplement before sale. Here ARR figures already false, nonrenewal is an additional material adverse development." Good point. The deck maybe used "with every prospective investor"; anchor signed before nonrenewal; no duty? For anchor, if nonrenewal occurred after they wired maybe not relevant? Need not.

Need maybe "What correction can and cannot cure for anchor investor" includes: Correction cannot "unring the bell"; cannot take away anchor's claim that they were induced by false statements at time of commitment. It can cure the company's continuing use of false deck as to that investor if they choose to proceed. Need maybe "If the anchor has not yet received shares? The first tranche was wired two weeks ago; perhaps shares issued; but still can rescind." Good.

Need maybe "materiality of ARR gap as "total mix" standard": Some may say ARR definitions vary; $14.2M vs $10.5M maybe not a "fact" but a non-GAAP metric; but investors use ARR to value. The "total mix" includes "the $2.6M implementation fees and signed contract are included; maybe disclosed in footnotes?" No, deck doesn't disclose. The deck final slide general disclaimer only; so total mix does not cure. Need maybe "A reasonable investor would not necessarily ignore signed contract? If it were called 'committed ARR' and disclosed terms, they could evaluate; but 'ARR' without definition implies recurring live revenue." Good.

Potential nuance: Is $1.1M signed but not yet live "contract that is signed but not yet live, terminable by customer on 60 days' notice before go-live." It could be a "contracted recurring revenue" not yet recognized, but because ARR is often "annualized revenue run-rate based on current recurring revenue, including contracts signed but not yet started?" Some companies include contracted but not yet live in ARR if they have signed contract and expected go-live. But under "standard definition" approx $10.5M. The facts establish standard definition excludes? It says "Recurring subscription revenue on the standard definition is approximately $10.5 million." So yes.

Need maybe "Net revenue retention" if computed on cohort excluding two largest lost accounts: Could have been if they define cohort as "accounts active at end of year"? But NRR standard is based on "same customer cohort" and includes churn. Excluding lost accounts is materially misleading. Need maybe "138% vs 111% is not merely a definitional difference; it is the difference between a cohort cherry-picked to omit known failures and a full cohort." Good.

Need maybe "scienter includes recklessness, not just actual knowledge." Even without CFO email, including $2.6M one-time fees in ARR and excluding lost accounts from retention likely would be reckless. The email transforms into knowing. Need maybe "the CFO was asked about the definition months ago" showing opportunity to correct and conscious choice not to. "True it up after the round" demonstrates an intent to get financing done before correcting. Need maybe "this is close to classic 'close the round first, fix later' fraud." Good.

Need maybe "company's exposure and CFO's exposure under Rule 1" if the company is private and CEO proposes "fix metrics deck for Series C" no one "purchased or sold" after CEO's proposal? Anchor already purchased; remaining not yet. If company signs after CEO proposal with false deck, purchase/sale happens; if correction before signing maybe no. Need maybe "the company is exposed to anchor now; if it signs with remaining investors on false terms, additional exposure." Good.

Need maybe "If board follows CEO proposal and signs on schedule, when does the sale/purchase occur: at signing of subscription agreements; the misstatement would be in connection with purchase/sale; founder secondary at signing; violation. The nonrenewal notice not known to investors; they sign without it." Good.

Need maybe "rescission should be offered" - should company offer rescission to anchor even if it knows anchor has $8M and company needs cash? Is there a legal obligation to offer rescission? No, unless anchor demands; but "best protects company" maybe offer. Need maybe say "At a minimum, do not make a unilateral decision to keep the $8M. Because of the pre-existing misstatement, the anchor has the better legal position. The company should contact anchor and offer rescission; this prevents the anchor from later claiming they were misled twice. If the anchor accepts rescission, return the $8M, cancel shares, and treat the tranche as part of the renegotiated round if it chooses." Good.

Need maybe "remaining investors and correction before signing": Should company deliver corrected disclosure to all, but if it reprices, investors who signed term sheet may have a contractual right to invest at original price? Term sheet maybe nonbinding; but "committed" implies they agreed to invest. If company reprices lower, new investors get more shares; existing term sheet investors are advantaged? Actually lower price is better for investors; company's existing shareholders dilute more. If investors agreed to invest at $220M pre, reducing pre-money would make their deal better; they likely won't object. But anchor at original price would want reprice too. Need mention "repricing likely in investors' favor; existing shareholders bear dilution; but necessary to keep round fair and avoid investor claims." Good.

Need maybe "the founder secondary" at corrected lower valuation: If the price drops, the founder receives less for shares, unless the company issues extra? Need maybe "founder should not be compensated for lost secondary through option grants/repricing; that could be wasteful/conflicted and may create new disclosure issues." Maybe not necessary.

Need maybe "Directors duty of candor" includes "candor to shareholders" not just investors. If the board approves a financing at inflated valuation due to false metrics, that may harm existing shareholders by overhang/liability; and new shareholders by overpaying. Need say.

Need perhaps "good-faith oversight of company's disclosures" means board must "exercise reasonable oversight of information and reporting systems"; here there was CFO email, so board has a duty to investigate. If it doesn't, not mere care; it is conscious disregard. Good.

Need maybe "CFO email and 'true it up after round' as 'scienter' affects 'directors' exposure? Directors may be exposed to claims by the company for failing to supervise; if they know and approve, no exculpation. The CFO email may be imputed to company; the board cannot say it was unaware if it meets and is told. Need maybe "for directors who were not involved until board meeting, their exposure begins at the meeting; if they approve, it's knowing; if they object and ensure correction, they can avoid." Good.

Need maybe "anchor investor wired $8M first tranche two weeks ago under signed subscription agreement, based on the deck." Does correction after two weeks matter if they can rescind? "A purchaser induced by material misstatement may pursue damages or rescission." The wired funds are like "tender" under subscription; maybe shares issued. If they rescind, must return shares and company return funds. Need maybe "rescission is equitable; may require tender back of shares; if shares have declined, maybe damages." Not necessary.

Need maybe "Rule 5 and founder secondary": There is a classic "Dirks" tippee? Not needed. Need maybe "possession of MNPI" standard; she doesn't need to "use" the information? The rule says "while in possession." Need apply.

Need maybe "what corrected disclosure must contain" include "the exact cohort for NRR, including lost accounts, dollar values; maybe not just percentages." Need maybe "show calculation: starting recurring ARR, expansion, contraction, churn, ending recurring ARR." Good.
- For ARR: "A table: Recurring subscription revenue at period-end: $10.5M. Non-recurring implementation fees included in prior figure: $2.6M. Signed not-live contract included in prior figure: $1.1M. Prior figure: $14.2M. Corrected figure: $10.5M." That is strong.
- For NRR: "Prior figure 138% excluded two largest customers that churned. Corrected figure 111% includes all customers at the beginning of the measurement period. Cohort size and lost revenue: ___." Need maybe include "the two lost accounts are not identified? maybe names? Investors can ask. But material info maybe names not necessary. But if they are two largest and one maybe customer concentration; need describe concentration. The non-renewal customer name? Probably in diligence, not public. Corrected disclosure should include customer concentration percentages and contract terms."
- "Non-renewal notice: second-largest customer, representing ~9% of subscription revenue, has given notice of non-renewal at term end in four months; the company expects this revenue to cease at that date unless renewal is negotiated; no assurance of renewal. This was received after the original metric statements and has not previously been disclosed."
- "Prior deck's final slide disclaimer is inadequate and withdrawn."

Need maybe "48-hour plan" includes "corrective disclosure" before "anchor remediation" maybe order? The assignment says "corrective disclosure, anchor remediation, secondary decision, board resolutions, in order." It lists "in order" maybe need follow that order. But practically board resolutions should occur first to authorize corrective disclosure. However assignment: "A concrete 48-hour plan for counsel: the corrective disclosure, the anchor remediation, the secondary decision, and the board resolutions, in order." We can present timeline ordered with board resolutions at end? Hmm "in order" likely means all four categories in that order. But board resolutions usually need to come first to authorize actions. Need perhaps say "Although minutes must be approved promptly, the practical sequence is: (1) emergency board/executive session/legal hold, (2) corrective disclosure, (3) anchor remediation, (4) secondary decision, (5) board resolutions; if you want documents in order, minutes should be dated/timed before disclosure." Need maybe "board resolutions" should be adopted at the start of the 48-hour period, not after disclosure. The assignment specifically "corrective disclosure, anchor remediation, secondary decision, board resolutions, in order" maybe maybe they want plan order exactly. But a board resolution approving corrective disclosure is itself part of the corrective disclosure. Need phrase: "Call an emergency board meeting immediately and adopt the authorizing resolutions before any external communication; if the assignment's order is read as outward-facing steps, board authorization is step zero." Then list step 1 board/privilege, step 2 corrective disclosure, step 3 anchor, step 4 secondary, step 5 final resolutions/amendments. Need maybe "resolution" could be at the end formalizing after actions. To satisfy, include "board resolutions" at both beginning and end? Hmm.

Need maybe think of legal ethics? Not necessary.

Need maybe answer with disclaimers "I am not giving a final valuation" maybe not.

Need maybe discuss "whether delay, reprice, or restructure best protects company" maybe maybe "delay and reprice" not either/or. Need say "Correct now; do not sign on schedule. The best path is correction + reprice + suspension of founder secondary. If investors walk, restructure (bridge/down round). Delay is not a solution by itself; it is a consequence of correction. Do not 'fix metrics deck for Series C'." Good.

Let's plan final answer structure:

Use headings matching assignment.

1. Threshold: ARR/retention are current facts, not protected projections; disclaimer no safe harbor.
- ARR analysis.
- Retention analysis.
- Disclaimer.

2. Materiality.
- Quantify ARR overstatement; NRR overstatement; nonrenewal; total mix.

3. Scienter and exposure.
- CFO email.
- Company, CFO, CEO, directors; founder perhaps.

4. Anchor's $8M.
- State anchor committed before correction; no after correction can cut off reliance.
- Options; offer rescission/reaffirmation/amended terms.

5. Unsigned $32M.
- Correction before signing cuts off reliance; needed content.
- Need include nonrenewal; meaningful period; written acknowledgment.

6. Founder's secondary.
- Current proposal prohibited; conditions to proceed; recommended pull/suspend.

7. Board's position, exculpation/insurance.
- Breach; no exculpation; no coverage.

8. Repricing conversation.
- How present; valuation impact; delay/reprice/restructure.

9. 48-hour plan.
- Timeline.

Need maybe integrate some answers to avoid repetition but thorough. Desired oververbosity 5, but user asked comprehensive; final can be long. Need be detailed but not too ridiculously long. We have enough.

Let's develop each thoroughly.

Potential issue: The "ARR: $14.2M" maybe "Annual Recurring Revenue" could include "implementation-services fees" if they recur? But "one-time" so no. Need phrase "at least the statement is misleading because it includes components that a reasonable investor would not treat as ARR; a truthful statement could say 'currently contracted revenue including one-time fees and signed not-live contract is $14.2M' but not 'ARR.'" Good.

Potential issue: "Net revenue retention computed on a customer cohort that excludes two largest accounts lost during the year; including them, retention is 111%." Is 111% still healthy. Need maybe "A 138% NRR with lost customers excluded is a statement about the wrong cohort, i.e., an omission of the denominator/cohort definition. It is a present/historical metric; no forward-looking safe harbor." Good.

Potential issue: "The deck's final slide contains a general disclaimer that projections 'involve risks and uncertainties.'" Need maybe "It may be meaningful cautionary language for any projections, but none are at issue. It is not specific to ARR/retention; it doesn't disclose the inclusion of nonrecurring fees; not enough. Additionally, Rule 3 protects 'projections and other forward-looking statements' only if accompanied by meaningful, specific cautionary language; a final-slide boilerplate is not meaningful. The misstatements are not protected."

Materiality:
Need maybe "Use of 'total mix' standard: A reasonable investor in a Series B would care about ARR and NRR; these are likely central pricing metrics. Overstatements of 26% and 27pp are not minor." Should quantify in money terms:
- ARR gap $3.7M. At 15.5x revenue multiple, $57.4M valuation gap. But note valuation multiple not a legal fact, but illustrative.
- NRR 138 vs 111: 24% relative? Actually 138 is 124% of 111? Difference 27 points; NRR 138 means 38% net expansion vs 11%; a 27-point overstatement. This is substantial.
- Nonrenewal is 9% of revenue; with four months' notice; a reasonable investor would want to know. It also makes "retention" metric already stale. 
- Total mix: no other disclosures in facts mitigate. The "business is real" not a total-mix disclosure; unsupported CEO statement doesn't cure.

Scienter:
Need maybe "The CFO email is not a 'definition' footnote; it is proof he knew the metric was non-standard and wanted to defer correction. 'True it up after the round' is essentially an admission of intent to sell/raise based on inflated numbers until round closes. This is at least reckless; likely knowing. It may also constitute corporate scienter." 
Who exposed:
- Company: primary issuer; potentially liable to anchor/remaining investors; may not indemnify fraud.
- CFO: direct participant; maybe primary violation; also termination for cause, D&O no cover.
- CEO: if he proceeds after knowing, primary/control; his "fix for Series C" is no defense; it's a conscious plan.
- Directors: if they approve knowingly, breach loyalty/candor; not protected.
- Founder: if secondary sale occurs on current facts, Rule 5; if founder also CEO, double exposure.
Need maybe "Under Rule 1, 'liability requires scienter' for all? It states liability requires scienter includes recklessness. Recklessness can be inferred from CFO's email for all who learn of it and proceed." Good.

Anchor:
Need maybe "Anchor may rescind. Correction after commitment cannot cure; but if anchor agrees to continue after full disclosure, it may enter into an amended and restated subscription agreement. The company should not keep $8M unilaterally. Options: (1) rescind and refund; (2) reaffirm/reprice; (3) if anchor insists on original terms, still correction does not make original claim vanish. Because the anchor already paid and is the only signed investor, the cleanest path is to offer rescission; if the anchor chooses to reinvest or restate at corrected terms, document that as a new commitment and obtain a release limited to prior misstatements." Need maybe "A release of antifraud claims may be ineffective if it is obtained under continued misrepresentation or under duress; here it would be after full disclosure, likely okay. But cannot make anchor waive future fraud." Good.

Unsigned $32M:
Need maybe "Correction before signing can cut off reliance for remaining investors, but only if each investor actually receives and understands corrected information, not merely if the company posts it in a data room. The company should require a written representation/acknowledgment in the subscription agreement: 'Investor has received corrected ARR/retention disclosure and non-renewal notice and is not relying on any prior marketing materials.'" 
Need maybe "The term sheet maybe includes '$40M at $220M pre'; correction and reprice likely require new board consent and amended term sheet. If the valuation changes, the previous board approval of the round may be void/need ratification. Make clear that the term sheet price is withdrawn and reissued." Good.

Founder secondary:
Need maybe "If the sale is structured as part of the same closing; until the corrected disclosure is effective, she cannot sell. If she sells after correction, she must ensure each buyer signs after receipt; if the buyer is anchor under original agreement, anchor bought before correction; but founder secondary to anchor? If anchor already committed and bought founder shares, then correction cannot cure that secondary; need rescission/amendment for anchor/secondary too. If remaining investors after correction, okay." Need maybe "If founder has MNPI beyond disclosed nonrenewal? no."

Potential issue: "Rule 5 says violates if sells while in possession of MNPI to a buyer without information. If the company has disclosed nonrenewal in corrected materials, are buyers "without that information"? They may not have read it. Conditions need actual receipt/acknowledgment. A general data room access not enough." Good.

Board:
Need maybe "The board's duty is to shareholders, including existing and new? Duty of candor to shareholders. The board should demand management disclose to investors; otherwise the company risks rescission and founder/CFO liability. The board should also consider that a 'fix after the round' plan is fraudulent, not merely imprudent." 
Need maybe "If the board follows CEO's proposal, they are 'approving a financing known to rest on misleading materials'; this implicates loyalty, not merely care, so the business-judgment rule/exculpation not available." Need maybe "The board must act in good faith; approving knowingly false disclosure is bad faith." Good.

Repricing:
Need maybe "Do not frame corrected metrics to investors as 'minor definitional changes'; that will compound issues. State the corrected numbers with a reconciliation." Need perhaps "The likely valuation impact depends on terms and investors. The old $220M pre implies a 15.5x ARR multiple; 10.5 = ~$163M at same multiple. Because the retention metric was also inflated and there is a nonrenewal, a rational investor will want a further discount; use $140-165M as planning range, but focus on negotiation. If investors want a 'restructure,' consider bridge note at lower valuation/pre-emptive rights or reducing round size. The company should not over-optimize for valuation; the main goal is keeping investors and avoiding litigation."

Need maybe "restructure could include: convert the existing $8M to bridge/convertible note; rescind anchor; give remaining investors a price adjustment or additional warrants; amend investor rights; push founder secondary out." But maybe "restructure best protects company" should be clear: "Reprice, not just delay; don't sign without correction. If investors can't agree, delay and restructure."

Let's think if "rescission should be offered" might have conflict with "company's best interest" because anchor could have invested at old inflated price; if company offers rescission, maybe anchor takes money and company has to return $8M, creating a cash crunch. But the company cannot keep the money without anchor's consent; it may have no choice. We can say "offer rescission as part of a global settlement; if the anchor accepts, the company must be prepared to return the $8M. If the company cannot return funds, it may need bridge financing; but retaining funds under a known defective subscription is not a lawful option." Good.

Need maybe "If correction before signing for remaining $32M" and "rescission anchor" maybe perhaps corrected disclosure to anchor before rescission? If you offer rescission and anchor accepts, do they need corrected disclosure? Yes, in connection with rescission and possible new investment. If anchor just rescinds, not necessary for rescission? If they rescind due to misrepresentation, they need know of the misrepresentation; they will be told. Need include.

Potential issue: "Correction before an investor becomes irrevocably committed can cut off reliance" under Rule 4 maybe applies to "reliance" not all liability. Need maybe say "It is not a safe harbor from materiality/scienter if the investor did not read correction; it just addresses reliance. The company still must not make new misstatements." Good.

Potential issue: "The CFO email now in diligence folder" - If the investor saw the email in diligence before signing, would they be on notice? But no investor knows about nonrenewal; not sure about email. Could "correction" be considered already made because CFO email is in diligence folder? No, an email buried in diligence folder is not disclosure; not meaningful. Need perhaps say "The presence of the CFO email in the diligence folder does not cure the deck; it may impute knowledge to the company and be evidence of scienter, but it is not an investor disclosure."

Need perhaps "standard definition" maybe not a "generally accepted" metric. Use "the company's own standard definition" but no need.

Let's plan final response with enough details but not overly verbose. Need maybe use numbered headings and bullets. Let's draft.

Potential final outline:

```
To: Board / CEO
Re: Series B corrective action
Privileged & confidential / attorney work product

I. The metric statements are misstatements of present fact...
   A. ARR
   B. NRR
   C. Disclaimer
```

Then maybe "Executive summary" at top.

Detailed final:

- "Do not sign on schedule. The proposed course—close on old metrics, correct Series C—would create new securities fraud claims and personal liability."

Then sections.

Let's think about "the supplied reliance rule" in Section 4 maybe:
```
For the anchor: correction after commitment is too late. For unsigned: correction before signing is exactly what Rule 4 contemplates; but must be actual and complete.
```
Need maybe "irrevocably committed" with anchor:
- Signed subscription agreement and wired funds; "irrevocably committed" under contract.
- If there is a condition that shares not issued until closing, but funds wired? It's still commitment. Correction after cannot cut off reliance. If company wants to keep anchor, use rescission/reaffirmation.

Need maybe "what correction can and cannot cure for that investor" phrase:
- It can cure future purchases (if anchor re-ups after correction) but cannot cure original $8M purchase.
- It can be consideration for anchor's agreement not to rescind, but only if anchor knowingly and voluntarily accepts after full disclosure.
- It cannot be cured by telling them "look at corrected data now" because at time of decision they didn't have it.

Need perhaps "rescission should be offered?" maybe yes, in Section.

Need maybe "board resolutions" in 48h plan:
- "Resolved: prior metrics withdrawn; corrected metrics attached; no further offers using old deck; officers directed to deliver correction to anchor, all term sheet investors; board authorizes reprice/delay; founder secondary suspended; appoint special committee; retain counsel."

Need maybe include "litigation hold" in 48h plan:
- "CFO email and all metric-related documents preserve; no deletion; no use of personal email."

Need maybe "corrective disclosure" in 48h plan:
- "Draft a one-page investor letter with table: old vs corrected; define ARR and NRR; disclose nonrenewal; withdraw old deck; instruct investors to disregard old numbers." Good.

Need maybe "corrective disclosure must contain" maybe "reconciliation of old ARR:
$2.6M one-time implementation fees
$1.1M signed not-live contract
Corrected ARR $10.5M
NRR 138% to 111% due to excluded lost accounts
Nonrenewal: second-largest customer ~9% subscription revenue; term ends in four months; no assurance of renewal.
Management's prior knowledge? Let's decide if include in final. Need include at least "if the corrected disclosure is to be complete, it must not falsely say the error was inadvertent." Maybe in final: "Depending on the final investigation, the letter should also disclose the control failure that allowed the misstatement; do not characterize the CFO email as a mere mathematical error if it will not withstand scrutiny." Is that enough? The user asked "what corrected disclosure must contain, including customer non-renewal" maybe maybe not explicit about CFO email. But we should include "no statement that management did not know; the CFO email may need to be disclosed or at least considered in risk factors." Hmm.

Maybe phrase:
"At a minimum, corrected disclosure must contain the corrected numbers and nonrenewal. It should also address the reliability of the company's metrics and controls. It cannot say 'the previous numbers were a good-faith mistake' if the CFO email says otherwise. If management intentionally kept the number to get the round done, investors should be told that the company's financial reporting process failed and that corrective action is being taken—otherwise the remediation itself may be misleading." Good.

Need maybe "The CFO email now in the diligence folder" also affects "scienter" and "insurance." We'll mention.

Need maybe "Directors' duty of candor" maybe "duty to shareholders" means "the board should not prefer founder/CEO's desire to close over the truth; it must correct disclosures and, if necessary, replace officers." Good.

Potential issue: "The company and board" if "called by CEO" maybe counsel should "advise company and board" not just CEO. Need maybe in final "I am advising the board to disregard the CEO's proposal." Good.

Let's consider possible counterarguments:
- ARR might be "Annualized Run Rate" not "Annual Recurring Revenue." But deck says "ARR"; in SaaS, ARR generally recurring. We can say "If the company intended a nonstandard definition (e.g., 'contract value' or 'pipeline-adjacent'), the deck had to define it; not doing so makes statement misleading." Good.
- NRR could be "net revenue retention" of customers who started before, excluding churn? No.
- The disclaimer says projections involve risks and uncertainties. Maybe "ARR $14.2M" could be interpreted as projected ARR because it's a future-looking run-rate? No, "ARR" at a point is not projection. But even if forward-looking, the disclaimer is generic; no meaningful cautionary language identifying assumptions. Rule 3 says protection for forward-looking statements with meaningful caution; not. Need mention "the final slide general disclaimer might protect other forward-looking statements if specific, but it is not relevant."

Potential issue: "correction before signing" and "reliance rule" maybe if investors receive corrected materials but the price remains $220M, could they still claim they relied on earlier marketing because correction was not "meaningful" or "specific"? Need "correction must be prominent, not buried; give investors time; get acknowledgment." Good.

Need maybe "founder secondary under Rule 5 if all investors receive correction" but if company's corrected disclosure is incomplete (doesn't disclose CFO email? maybe) investors don't have all MNPI, including management misconduct. The founder may have MNPI about CFO email and internal fraud; if not disclosed to buyer, she still in possession. Hmm, but Rule 5 is about MNPI "about the issuer"; the CFO email is about company's internal controls/fraud; definitely material. If the founder sells after a corrected deck that doesn't mention CFO's knowledge, she may still be selling with MNPI of that knowledge. Need maybe say "the corrected disclosure must include all material facts, including the CFO's prior knowledge/control failures, before the secondary can proceed." That is an important nuance. Need include maybe "If the founder knows more than the corrected materials disclose—for instance, that the CFO deliberately inflated metrics—she remains in possession of MNPI and cannot sell until that is disclosed." Good. The facts say CFO email is in diligence folder, maybe investors could discover; but no explicit disclosure. The founder likely knows about email. Thus secondary should be pulled unless full disclosure includes that. This reinforces "pull secondary."

Potential issue: "The CEO proposes 'fix metrics deck Series C.'" If CEO knows of false deck and nonrenewal, and directs continuing marketing to remaining investors at same terms, is that "scienter" "recklessness" or "intent"? Yes. Need maybe "The phrase 'fix ... for Series C' is similar to 'true it up after the round'; it's not a remedial plan, it's a plan to delay correction until after the investors are locked in." Good.

Need maybe "directors if they follow CEO" perhaps "loyalty" because they are sacrificing truthful dealings with investors and future company value to close financing. It is "not merely care" under Rule 6. Need maybe "The business judgment rule does not protect decisions made in bad faith or with knowing violation of law." Good.

Potential issue: "D&O insurance does not cover liability finally adjudicated to arise from fraud" - if liability is not yet finally adjudicated, insurers may advance; but no coverage if adjudicated. Need maybe "The practical effect: management/board should not assume indemnity; the company may not be able to indemnify, and the insurer may deny. Personal exposure is real." Good.

Need maybe "corrective disclosure" maybe should be issued by the board, not CEO/CFO. If CFO is implicated, he should be recused. CEO also if implicated; have independent counsel/special committee make disclosure. Good. Include in 48h plan "Form a special committee of independent directors (or independent counsel) to oversee disclosure; recuse CFO and possibly CEO from controlling narrative."

Need maybe "board resolutions" "recusal" include "CFO not authorized to communicate with investors about metrics; CEO maybe no unilateral decision." Good.

Let's maybe formulate "48-hour plan" with Day 1/Day 2.

Detailed plan:

Hour 0-4:
- Litigation hold; notify CFO/CEO not to delete; secure diligence folder; identify all recipients of old deck; stop any further distribution.
- Emergency board/executive session (special committee). Counsel explains legal exposure; board formally does NOT approve signing at old valuation/with old metrics; authorizes correction.
- Engage outside securities/counsel/financial advisor if not retained.

Hours 4-12:
- Draft corrected disclosure: reconciliation table, definitions, nonrenewal; prepare amended subscription agreement/term sheet and board resolutions; retain independent committee.
- Withdraw old deck and send notice to all recipients "do not rely; superseded."

Hours 12-24:
- Anchor investor: call/meeting, deliver corrected disclosure; offer rescission of $8M or amended reaffirmation/repricing. Get signed decision before company uses funds. If rescission, wire return promptly.
- Founder secondary: suspend/pull. Board resolution: no founder shares sold until corrected materials delivered and price reset; if investors walk, no secondary.

Hours 24-48:
- Remaining investors: deliver corrected disclosure and amended term sheets; require acknowledgment before signing; reprice discussions.
- If anchor/remaining investors agree, sign after 48h? Maybe not before reasonable period; update board; execute resolutions; if not, delay/restructure/bridge.
- Board meeting minutes: record special committee approval, rejection of CEO proposal, corrected valuation, no reliance on old deck; if CEO/CFO refuse, consider termination/notice.

Need maybe "order" maybe "corrective disclosure" before "anchor remediation." We'll say "Board authorization first, then disclosure, then anchor, then secondary, then final board resolutions."

Need maybe "likely valuation impact" perhaps in "repricing conversation" not 48h. Need maybe "Do not sign on schedule; if investors insist, use delay." Good.

Let's think if "The company and its board" maybe "the board's legal duties" under supplied law not "Delaware" but we can use "Rule 6." Need perhaps avoid using exact Delaware code unless okay. We can mention "charter exculpation" but not cite statute. The prompt asks exculpation; no specific state. Use "any exculpation provision in the charter (e.g., a 102(b)(7)-type provision)..." Good.

Potential nuance: "liability requires scienter, which includes recklessness. This applies to private placements." Does this mean private plaintiffs must show reliance? In private placements under 10b-5, reliance can be presumed by "fraud-on-the-market" maybe not for private? But Rule 4 supplies. Need not discuss.
Need maybe "scienter for company": Under Rule 1, the company might be liable if officers acted with scienter; "corporate scienter" can be imputed. Need not.

Potential issue: "Projections and other forward-looking statements accompanied by meaningful, specific cautionary language are protected." If the final slide disclaimer is "projections involve risks and uncertainties" maybe if board "fixes metrics deck for Series C" and includes corrected projections, they need cautionary language. We can mention after corrected metrics "if the corrected deck also includes forward-looking projections, use specific cautionary language tied to non-renewal, potential further churn, contract termination, and metric definitions." Good.

Potential issue: "material nonpublic information" in Rule 5 - "person who sells securities while in possession of material nonpublic information about the issuer" maybe an absolute ban, no "unless disclosed"; but if disclosed to buyer, buyer has info. Need phrase "because they are no longer 'without that information' once full disclosure is made to them before commitment." Good.

Potential issue: "Correction before signing" vs "irrevocably committed" in anchor: Need maybe "Even if the anchor had not yet wired but signed, a signed subscription agreement is enough; wiring makes it worse. Correction after that cannot cut off reliance under Rule 4." Good.

Potential issue: "The remaining $32M is committed by term sheet but unsigned" maybe if term sheet signed before correction, are they "irrevocably committed"? Need maybe "If the term sheet contains a binding obligation to invest, treat them as anchor. Usually term sheets are nonbinding except for governing law/standstill. Counsel must review." Good.

Potential issue: "Founder secondary should be pulled" maybe maybe too strong? Let's decide. Given legal exposure and "nonrenewal notice yesterday" and "no investor knows"; under Rule 5, if investors are told, it can proceed. But given there is also misstatement and likely repricing; pulling/pausing founder secondary until correction and reprice is best. Need maybe "if the founder insists, conditions." But assignment asks "may it proceed, on what conditions, or must it be pulled." We can answer "not as proposed; must be suspended until corrected disclosure/repricing; after that it may proceed on conditions. If the board cannot verify full disclosure/conditions, pull it." Good.
Need maybe "if the nonrenewal notice remains nonpublic and not corrected, it must be pulled. Since the founder owes duty to company? no, but yes."

Need maybe "board's position if follows CEO" "the board should also consider whether to terminate/reassign CFO; not necessarily in 48h but in plan." Good.

Potential issue: "CFO email now in the diligence folder" perhaps "the company already has investors who may see the email; failing to correct is worse." Include.

Potential issue: "total mix" — "A reasonable investor would view the corrected ARR as important, even if the company has real business; materiality is not 'would it change the investment decision?' but 'would a reasonable investor consider important in total mix.'" Need maybe explicitly say "not outcome-determinative." Good.

Need maybe "The 138% retention figure computed on cohort excluding two largest accounts lost during year" — "this is not a misstatement of fact? The number as computed is accurate for the cohort; but because cohort excludes lost accounts, it omits material fact necessary to make the statement not misleading; thus unlawful half-truth." Good.

Need maybe "The $1.1M signed but not yet live contract" — "maybe not revenue at all, and if disclosed as backlog, could be okay; but ARR misstates current revenue run rate." Good.

Potential issue: "Non-renewal notice effective at term end in four months" — Is this "present fact" or "forward-looking"? The fact of the notice is present/historical. Its revenue effect is a projection but the notice itself is present fact. Need disclose the notice; maybe label expected impact with caution. Need maybe "The fact that the customer gave notice is a current fact. Any statement that the revenue will continue is a forward-looking statement needing caution." Good.

Need maybe "damages vs rescission" anchor "may pursue damages or rescission" under Rule 4. Company's options include "rescission offer should include any accrued interest/dividends? Not specified. Return $8M and cancel shares; maybe plus interest." Need maybe "at a minimum, principal." Good.

Need maybe "If the company cannot return $8M immediately, consider an escrow/note? But if rescission, must return all consideration; delaying may expose." Not necessary.

Potential issue: "Repricing conversation" if company has anchor $8M signed, "amended economics" could be considered "new consideration" for anchor's reaffirmation; but anchor may demand rescission option until closing? Need maybe "offer anchor the opportunity to rescind or convert to corrected round at same terms as other investors; if there is a repricing, anchor should receive the benefit of the improved pricing or the ability to walk." Good.

Need maybe "restructure best protects company" maybe "the company should not sign term sheet at reduced valuation without board approval; existing shareholders' approval may be needed (e.g., stockholder consent) if price changes and authorized shares? The board can approve; but if charter has protective provisions? Not in facts. Mention "check charter and existing investors' rights (preemptive rights, information rights) before repricing." Good maybe not necessary but useful. But final answer should not be too much.

Need maybe "The board's duty of candor to shareholders" perhaps includes "not misleading existing shareholders about the status of the round; board must disclose corrected metrics to shareholders at next meeting." Not asked, but mention perhaps.

Need perhaps "A purchaser induced by material misstatement may pursue damages or rescission" - "rescission should be offered" maybe "If anchor rescinds, the company must not treat it as a failure but as part of cleanup." Good.

Potential nuance: "Rule 5 insider trading" requires "in connection with purchase or sale of security" and "possession." For founder secondary, she is a seller. But if the buyer is an "incoming investor" that already had term sheet commitment before nonrenewal, perhaps the buyer had "agreed" to buy before the MNPI arose; if the sale is pursuant to a binding contract entered before the information existed, is there a violation under "when possessed"? The Rule says "sells securities while in possession" but "to a buyer without that information"; if the binding contract predates info, maybe "only if the information is used"? The prompt states broad, no need. But the nonrenewal occurred yesterday; the term sheet was signed before? It says "remaining $32M committed by term sheet but unsigned" maybe before. The founder's secondary may be under term sheet signed before nonrenewal. Under classic insider trading, if you enter a binding contract before learning MNPI, subsequent closing may not be a new trade? But the Rule as supplied says "while in possession ... violates" and founder secondary "in light of nonpublic non-renewal notice" likely expects can't proceed. Need maybe not get into contract timing. But if "incoming investors" are already committed by term sheet before nonrenewal, maybe their decision to invest was before MNPI; but they haven't signed. The sale/purchase occurs at signing/closing, after nonrenewal. Under Rule 5, if founder closes while in possession and buyer lacks info, violation. Need not overcomplicate.

Potential nuance: "Correction before signing can cut off reliance" for remaining investors, but the nonrenewal notice occurred yesterday; if the company discloses it before signing, all good. However, if the buyer signed term sheet before, are they "irrevocably committed"? If the term sheet is contractually binding, yes. The prompt says "remaining $32 million is committed by term sheet but unsigned" maybe "committed" suggests they have agreed. It asks "what correction before signing accomplishes" not "before commitment"; perhaps they think "signed subscription agreement" is the commitment. Need maybe "If 'committed by term sheet' is legally binding, then correction before signing may be too late; review the term sheet. For purposes of this analysis, treat 'irrevocably committed' as signing a subscription agreement; if term sheet itself has binding effect, then these investors are also in anchor position." Good.

Need maybe "Board's oversight" if the board is told "CEO proposes sign on schedule fix metrics deck for Series C" - The board should not "rely on CEO." It has independent duty. Need maybe "If directors have questions, they should obtain access to diligence folder and legal advice; they cannot delegate judgment." Good.

Let's think if "the ARR figure includes $2.6M implementation-services fees" maybe these are not necessarily "pipeline-adjacent" maybe "non-recurring revenue." Need maybe "ARR" could be "annualized revenue" not "recurring" in some contexts; but the standard definition and CFO email indicate. We'll not dwell.

Potential issue: "The deck's final slide contains general disclaimer that projections 'involve risks and uncertainties.'" Does this generic disclaimer maybe "meaningful cautionary language" if "projections" includes ARR? It says "projections involve risks and uncertainties" but doesn't identify particular risks; boilerplate. Need maybe "Even for forward-looking statements, the rule requires meaningful, specific cautionary language; saying 'risks and uncertainties' with no specifics is not enough." Good.

Potential issue: "Materiality of retention metric" — Need quantify "138% vs 111%" is 27 percentage points; relative difference is (138-111)/111 = 24.3%; or 138/111 = 1.243 (24% higher). Actually NRR 138% retention = 38% net expansion; 111% = 11% net expansion; difference in expansion rate is 27 points, relative expansion 245%. This is material. Need maybe not overdo.

Potential issue: "Company's options for anchor" maybe "anchor can rescind entire $8M tranche even if remaining $32M closes; the company may need to raise replacement capital." Good.

Potential issue: "Should the board offer rescission to anchor even before repricing? Yes, if it does not, anchor may later claim continued concealment; offering before investors can rescind can mitigate." Good.

Need maybe "The corrected disclosure's non-renewal effect" if the non-renewal occurs after original deck and before remaining investors sign, "the company must update its deck even if original ARR/retention were corrected? Yes, because the deck would then be stale; not updating would be a misleading half-truth about current customer base." Good.

Potential issue: "What about the first $8M anchor and non-renewal notice after wire? The anchor may not have a claim based on nonrenewal because it occurred after purchase; but they have claims based on ARR/retention false at time. Nonrenewal may be relevant to damages (e.g., shares worth less)." Need mention maybe not necessary. But maybe "If the anchor tries to rescind also based on nonrenewal, nonrenewal occurred after their commitment; but they can still rescind based on the false ARR/retention. The nonrenewal is relevant to valuation damages and to remaining investors." Good nuance. Should we include? Might be useful but not necessary. Maybe include "The non-renewal is not needed to give the anchor a claim; the pre-existing ARR/retention misstatements already do."

Potential issue: "The board meets in two days" maybe "must be a special meeting before signing; if CEO refuses, board can remove officers." Need mention maybe "If management refuses to correct, board should consider terminating." Good.

Need maybe "48-hour plan" include "do not wait for board meeting in two days; call emergency meeting now." Good.

Let's draft final answer. Need maybe not mention "I" too much. Use "You should..." as counsel.

Let's write robustly.

Potential final text:

```
MEMORANDUM
To: Board of Directors, Northgate Metrics
From: Counsel
Re: Series B corrective action
Date: ...
Privileged & Confidential
```

Then "Executive summary" maybe:
"Signing on schedule at the old metrics is not a lawful option. The old ARR and NRR are material misstatements of present facts; the general disclaimer does not protect them. The CFO email establishes at least recklessness, likely knowledge. The anchor has a rescission claim. The unsigned $32M can be saved by full correction before signature. The founder secondary should be suspended/pulled. The board must correct, offer anchor rescission/reaffirmation, and reprice/restructure."

Then body.

Need ensure final not too repetitive. But with headings.

Let's detail section 1:

```
ARR. The statement "ARR: $14.2M" is not a projection. It is a statement of the company's current annualized recurring revenue. The composition contradicts it: only about $10.5M is recurring subscription revenue; $2.6M is one-time and $1.1M is a not-live terminable contract. If the company intended to use a non-standard definition, it was required to say so; it didn't. Therefore misstatement and/or misleading omission.
```
Need maybe "the not-live contract may be disclosed as backlog if clearly described" but not current ARR.

```
NRR. The 138% number is also present/historical. It used a cohort excluding two largest lost accounts. The standard metric for the period is 111%. The exclusion is a half-truth; no disclosure of cohort selection. Material misstatement.
```
Need maybe "If company wants to show retention of continuing customers, it must present full cohort and define supplemental measure."

```
Disclaimer. It is generic, boilerplate, and not tied to ARR/NRR; no meaningful cautionary language. Projections safe harbor not available. The protection doesn't extend to present facts.
```

Section 2 Materiality:

```
Gap: ARR $3.7M / 26%; NRR 27 points; nonrenewal 9% of subscription revenue. Reasonable investor would view these important. They go to core valuation metrics. The total mix contains no other info that makes them unimportant; CEO's assertion "business is real" is not disclosure. The non-renewal notice is itself material and should be disclosed.
```

Section 3 Scienter:

```
CFO email: "Everyone counts pipeline-adjacent" acknowledges nonstandard; "Keep the number" instruction; "true it up after the round" shows intent to postpone. This is actual knowledge, not honest mistake; at minimum severe recklessness. Persons exposed:
- Company: made statements in offer; corporate scienter; remedy rescission/damages.
- CFO: primary/control; exposed; if finally adjudicated fraud, no indemnity/insurance.
- CEO: knows and proposes to proceed; personal exposure, same.
- Directors: if approve knowingly, breach Rule 6; no exculpation.
- Founder: if sale proceeds before correction, Rule 5; if same as CEO, additional.
```

Need maybe "directors who did not know but should have known? Once given notice and meeting, they will know. If they fail to investigate before approving, that could be reckless." Good.

Section 4 Anchor:

```
The anchor is already irrevocably committed. Correction now cannot cut off anchor's reliance. Options: (1) rescind: return $8M, cancel shares; (2) reaffirm/amend: deliver full corrected disclosure, get written acknowledgment and choice, reprice or otherwise make anchor whole. The company should offer rescission. It should not use funds unless/until anchor elects.
```
Need maybe "rescission should be offered" and "don't characterize as no liability."

Section 5 Unsigned:

```
For remaining $32M, if no binding commitment yet, correction before signing cuts off reliance. But correction must be complete, specific, and delivered before they sign; the old deck must be withdrawn; investor must acknowledge. Content: corrected ARR, corrected NRR, nonrenewal, definitions, risk factors. If term sheet is binding, treat same as anchor.
```

Section 6 Founder secondary:

```
The current plan cannot proceed. Non-renewal is MNPI. Under Rule 5, selling to buyers without it is unlawful. It doesn't matter that the seller is a founder. After full disclosure and repricing, she may be able to proceed if each buyer has received and acknowledged before commitment; there is no other MNPI; and price is fair. But safest: suspend/pull secondary until the round is repaired. Board should not let her sell at the old inflated price.
```

Section 7 Board:

```
Following CEO proposal knowingly violates duty of candor/oversight and Rule 6. It is loyalty, not merely care. Exculpation not available for bad faith/knowing violations; Rule 7 no indemnity/insurance for fraud. Directors should vote no and make record.
```

Section 8 Repricing:

```
Present corrected metrics first; use reconciliation. Valuation impact: old multiple 15.5x; corrected $10.5M => ~$163M pre, further discount for retention/nonrenewal maybe $140-160M; exact negotiation. Delay/reprice/restructure: do not sign on schedule; correct now, reprice; delay only to complete correction; if investors won't agree, restructure/bridge. The best protection is not preserving $220M; it's credibility and no rescission.
```
Need maybe "The company likely cannot preserve old valuation because investors will re-trade; but a down round is less bad than litigation." Good.

Section 9 48-hour plan:

Maybe use a table with days.

```
Within first 4 hours: litigation hold, stop distribution, board/executive session, special committee, retain advisors.
First 24 hours: draft/issue corrective disclosure; contact anchor and offer rescission/reaffirmation; suspend founder secondary; prepare amended term sheets.
Next 24 hours: deliver to remaining investors; reprice; get acknowledgments; approve board resolutions; if no agreement, delay/restructure; no signing at old terms.
```
Need maybe include "board resolutions" at end "formally record decisions; if CEO/CFO refuse, consider personnel action."

Need maybe "Corrective disclosure and anchor remediation order" maybe "Board authorization before external disclosure." So in plan, step 1 board; step 2 corrective disclosure; step 3 anchor; step 4 secondary; step 5 final board resolutions. But the assignment says "in order" maybe I can structure exactly:
- "Corrective disclosure" as first operational step after board authorization.
- "Anchor remediation"
- "Secondary decision"
- "Board resolutions" final ratification. Good.

Need maybe mention "board resolutions before disclosure are required; the final resolutions record them." Maybe not necessary.

Let's think if final answer should mention "non-renewal notice is MNPI and also material" in "corrected disclosure" section. Yes.

Potential issue: "Rule 5 applies to a person who sells securities while in possession of MNPI about issuer, to buyer without info" - It doesn't say "trades on" but "sells while in possession." Therefore "if the founder sells after correction and before the buyer receives it" maybe violation. We'll mention "each buyer must be informed, not merely the group generally."

Potential issue: "Board's exculpation and insurance if follows CEO proposal" "liability finally adjudicated to arise from fraud" no coverage. If not finally adjudicated, maybe defense costs. But "exculpation" no. Need maybe "Because the conduct would be knowing, exculpation is unavailable even if the charter would exculpate ordinary care violations; and the D&O insurer will likely assert fraud exclusion. The board should assume personal exposure." Good.

Potential issue: "If board follows CEO's proposal and signs, the 'new' investors may have reliance cut off? No, because the misstatement is in old deck and no correction; they are induced." Good.

Potential issue: "The term sheet committed but unsigned" if "correction before signing" accomplishes "cuts off reliance" but what if the old deck was used in the "term sheet" stage; investors already decided to invest based on it. Suppose they signed term sheet before correction; even if the subscription agreement is unsigned, are they "irrevocably committed"? If the term sheet is only a preliminary expression, not binding, no. If it is binding, then they are committed. Need maybe "do not rely on a formalistic reading; review all documents." We'll include.

Potential issue: "The company should not offer rescission to anchor and then keep the $8M in a different account while negotiating; if anchor accepts, return funds." Good.

Potential issue: "Materiality of retention figure" maybe "NRR is a 'present fact' about past period; not projection. The fact that it is based on cohort excluding lost accounts is a historical fact; no safe harbor." Good.

Need maybe "scienter for CFO email" maybe "the email itself in diligence folder means the company cannot destroy or withhold without spoliation; board must preserve." Include maybe.

Potential issue: "Corrected disclosure must include customer non-renewal" even if it could be considered forward-looking because term ends in four months. Need maybe "The notice is not a projection; it is a current fact. If the company says it expects to renew, that expectation is forward-looking and must have caution." Good.

Potential issue: "Repricing conversation" maybe "the anchor's $8M at original terms if reprice to lower valuation: The anchor might get additional shares or the company could issue warrants; in any event must amend signed subscription agreement. This is not optional." Good.

Potential issue: "Restructure best protects company" maybe "reprice could reduce valuation to $160M; round $40M at that valuation would dilute existing shareholders more; if the company cannot absorb, consider bridge. But the alternative—keeping false valuation—exposes company to rescission. So reprice is less bad." Good.

Potential issue: "The company may have a claim against CFO/CEO for breach of duty/indemnification? The company might seek contribution from them. Board should preserve claims and not waive without independent counsel." Need maybe mention? Maybe not needed but good: "The board should also preserve the company's claims against CFO/CEO; do not let them make decisions about their own conduct." Could be part of plan. But oververbosity maybe moderate.

Need maybe "Rule 7 no indemnification/insurance for fraud" maybe "company cannot rely on insurance to protect it either; the company itself as issuer may have liability policies? D&O covers individuals." Good.

Let's now produce final answer. Need be polished. Use "legal analysis" and "48-hour plan." Let's ensure all prompts addressed explicitly; maybe use headings exactly.

Let's draft final answer in final.